Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification).
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
entrez:
9
8
2022
pubmed:
10
8
2022
medline:
12
8
2022
Statut:
ppublish
Résumé
The management of endometrial cancer has known many evolutions within the last decades. In this review, we aim to summarize recent evolutions (mainly toward less aggressive management) that have occurred in the management of endometrial cancer. Enhanced by molecular classification, the determination of lymph node status, in young women, in case of cervical invasion, the treatment is evolving toward a less aggressive strategy. The predictive value and the safety of sentinel lymph node biopsy explain why most societies propose to abandon systematic pelvic and para aortic lymphadenectomy. For young women, the safety of fertility preservation is now well established and efficient protocols have been validated. In stage II endometrial cancer (stromal cervical invasion), radical hysterectomy appears excessive. The Cancer Genome Atlas classification increases prognostic evaluation in association with the traditional pathological classification and permits to tailor adjuvant treatment more accurately.
Identifiants
pubmed: 35943439
doi: 10.1097/CCO.0000000000000874
pii: 00001622-202209000-00014
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
511-517Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Koskas M, Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet 2021; 155:45–60.
Koskas M, Rouzier R, Amant F. Staging for endometrial cancer: the controversy around lymphadenectomy - can this be resolved? Best Pract Res Clin Obstet Gynaecol 2015; 29:845–857.
Dowdy SC, Borah BJ, Bakkum-Gamez JN, et al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol 2012; 127:5–10.
Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008; 100:1707–1716.
Kitchener H, Swart AMC, Qian Q, et al. ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373:125–136.
Hamilton CA, Pothuri B, Arend RC, et al. Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations. Gynecol Oncol 2021; 160:817–826.
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31:12–39.
Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019; 69:258–279.
Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016; 26:2–30.
Lee TS, Kim JW, Kim DY, et al. Necessity of radical hysterectomy for endometrial cancer patients with cervical invasion. J Korean Med Sci 2010; 25:552–556.
Visser NCM, Reijnen C, Massuger LFAG, et al. Accuracy of endometrial sampling in endometrial carcinoma: a systematic review and meta-analysis. Obstet Gynecol 2017; 130:803–813.
Kandoth C, Schultz N, Cherniack AD, et al. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67–73.
Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017; 123:802–813.
Timmerman S, Van Rompuy AS, Van Gorp T, et al. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. Gynecol Oncol 2020; 157:245–251.
Nagar H, Wietek N, Goodall RJ, et al. Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer. Cochrane Database Syst Rev 2021; 6:CD013021.
Persson J, Salehi S, Bollino M, et al. Pelvic Sentinel lymph node detection in high-risk endometrial cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging. Eur J Cancer 2019; 116:77–85.
Cusimano MC, Vicus D, Pulman K, et al. Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg 2021; 156:157–164.
Ducie JA, Eriksson AGZ, Ali N, et al. Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecol Oncol 2017; 147:541–548.
Helgers RJA, Winkens B, Slangen BFM, Werner HMJ. Lymphedema and post-operative complications after sentinel lymph node biopsy versus lymphadenectomy in endometrial carcinomas-a systematic review and meta-analysis. J Clin Med 2020; 10:E120.
Garzon S, Mariani A, Day CN, et al. Overall survival after surgical staging by lymph node dissection versus sentinel lymph node biopsy in endometrial cancer: a national cancer database study. Int J Gynecol Cancer 2022; 32:28–40.
de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and posthoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; 20:1273–1285.
Chae SH, Shim SH, Lee SJ, et al. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Int J Gynecol Cancer 2019; 29:77–85.
Di Spiezio Sardo A, De Angelis MC, Della Corte L, et al. Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer? Gynecol Oncol 2020; 158:347–353.
Larish A, Kumar A, Weaver A, Mariani A. Impact of hysteroscopy on course of disease in high-risk endometrial carcinoma. Int J Gynecol Cancer 2020; 30:1513–1519.
Guillon S, Popescu N, Phelippeau J, Koskas M. A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma. Int J Gynaecol Obstet 2019; 146:277–288.
Chabbert-Buffet N, Amoura Z, Scarabin PY, et al. Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception 2011; 83:229–237.
Ouasti S, Bucau M, Larouzee E, et al. Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women. Int J Gynaecol Obstet 2021; 157:452–457.
Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:748–758.
Hall C, Stone RL, Gehlot A, et al. Use of metformin in obese women with Type I endometrial cancer is associated with a reduced incidence of cancer recurrence. Int J Gynecol Cancer 2016; 26:313–317.
Dowling RJO, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011; 9:33.
Chae-Kim J, Garg G, Gavrilova-Jordan L, et al. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2021; 31:1499–1505.
Yang BY, Gulinazi Y, Du Y, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well differentiated endometrial cancer: a randomised controlled trial. BJOG 2020; 127:848–857.
Koskas M, Bendifallah S, Luton D, et al. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril 2012; 98:1229–1235.
Koskas M, Yazbeck C, Walker F, et al. Fertility-sparing management of grade 2 and 3 endometrial adenocarcinomas. Anticancer Res 2011; 31:3047–3049.
Shan W, Wu P, Yang B, et al. Conservative management of grade 2 stage IA endometrial carcinoma and literature review. J Obstet Gynaecol Res 2021; 47:984–991.
Hwang JY, Kim DH, Bae HS, et al. Combined oral medroxyprogesterone/levonorgestrel-intrauterine system treatment for women with Grade 2 Stage IA endometrial cancer. Int J Gynecol Cancer 2017; 27:738–742.
Gonthier C, Trefoux-Bourdet A, Koskas M. Impact of conservative managements in young women with Grade 2 or 3 endometrial adenocarcinoma confined to the endometrium. Int J Gynecol Cancer 2017; 27:493–499.
Casadio P, La Rosa M, Alletto A, et al. Fertility sparing treatment of endometrial cancer with and without initial infiltration of myometrium: a single center experience. Cancers (Basel) 2020; 12:E3571.
Britton H, Huang L, Lum A, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol 2019; 153:487–495.
Falcone F, Normanno N, Losito NS, et al. Application of the proactive molecular risk classifier for endometrial cancer (ProMisE) to patients conservatively treated: outcomes from an institutional series. Eur J Obstet Gynecol Reprod Biol 2019; 240:220–225.
Herrera Cappelletti E, Humann J, Torrejón R, Gambadauro P. Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis. Hum Reprod Update 2022; 28:282–295.
Vaugon M, Peigné M, Phelippeau J, et al. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management. Reprod Biomed Online 2021; 43:495–502.
Signorelli M, Lissoni AA, Cormio G, et al. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol 2009; 16:3431–3441.
Takano M, Ochi H, Takei Y, et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer 2013; 109:1760–1765.
Phelippeau J, Koskas M. Impact of radical hysterectomy on survival in patients with stage 2 Type 1 endometrial carcinoma: a matched cohort study. Ann Surg Oncol 2016; 23:4361–4367.
Watanabe Y, Satou T, Nakai H, et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol 2010; 116:1027–1034.
Gu H, Li J, Gu Y, et al. Survival impact of ovarian preservation on women with early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2017; 27:77–84.
Lyu T, Guo L, Chen X, et al. Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study. J Int Med Res 2019; 47:2492–2498.
Vandenput I, Van Calster B, Capoen A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer 2009; 101:244–249.
Huang AB, Wu J, Chen L, et al. Neoadjuvant chemotherapy for advanced stage endometrial cancer: a systematic review. Gynecol Oncol Rep 2021; 38:100887.
Wright JD, Huang Y, Melamed A, et al. Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. Gynecol Oncol 2021; 162:599–605.
Carlson J, McCluggage WG. Reclassifying endometrial carcinomas with a combined morphological and molecular approach. Curr Opin Oncol 2019; 31:411–419.
Hoang LN, Kinloch MA, Leo JM, et al. Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on The Cancer Genome Atlas (TCGA)-based molecular subgroup. Am J Surg Pathol 2017; 41:245–252.
Vrede SW, van Weelden WJ, Visser NCM, et al. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecol Oncol 2021; 161:787–794.
Karnezis AN, Leung S, Magrill J, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res 2017; 3:279–293.
van der Putten LJ, Visser NC, van de Vijver K, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer 2016; 115:716–724.
Trovik J, Wik E, Werner HMJ, et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer 2013; 49:3431–3441.
McConechy MK, Talhouk A, Leung S, et al. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin Cancer Res 2016; 22:2865–2873.
León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020; 38:3388–3397.
McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244:538–549.
DeLair DF, Burke KA, Selenica P, et al. The genetic landscape of endometrial clear cell carcinomas. J Pathol 2017; 243:230–241.
Espinosa I, Lee CH, D’Angelo E, et al. Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Am J Surg Pathol 2017; 41:1121–1128.
Huvila J, Pors J, Thompson EF, Gilks CB. Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. J Pathol 2021; 253:355–365.
Kasius JC, Pijnenborg JMA, Lindemann K, et al. Risk stratification of endometrial cancer patients: FIGO stage, biomarkers and molecular classification. Cancers (Basel) 2021; 13:5848.
van den Heerik ASVM, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 2020; 30:2002–2007.
Amant F, McCluggage WG, Werner HMJ, et al. Incorporating molecular profiling into endometrial cancer management requires prospective studies. Int J Gynecol Cancer 2021; 31:944–945.